secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-07-23T23:59:59+00:00
Accession:  0000950170-24-085653
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

KalVista Pharmaceuticals enters lease for HQ and lab in Framingham; aggregate rent ~$11.2M
--------------------------------------------------------------------------------

- Lease for 32,110 sq ft at 200 Crossing Blvd, Framingham, MA, as corporate HQ and lab space.
- Commencement on or about April 30, 2025; lease expires December 31, 2034.
- Aggregate base rent payments of approximately $11.2 million over the term.
- Security deposit of ~$652,800 in the form of a letter of credit.
- Company to pay pro rata share of operating expenses and certain taxes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024085653/0000950170-24-085653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024085653/kalv-20240722.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-085653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer